FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
WATERTOWN, Mass., Sept. 22, 2016 -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced today that Nancy Lurker, the Company’s newly-appointed President and Chief Executive Officer, is scheduled to present at the Ladenburg Thalmann Annual Healthcare Conference on Tuesday, September 27, 2016 at 1:30 pm. ET. The conference will be held at the Sofitel Hotel in New York City.
The presentation will be webcast at http://wsw.com/webcast/ladenburg2/psdv and a link will also be available at the Company's website.
About pSivida Corp. pSivida Corp. (www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release drug delivery products primarily for eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the United States and three E.U. countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida’s lead product candidate, Medidur™, a micro-insert for posterior uveitis being independently developed, is currently in pivotal Phase 3 clinical trials, with an NDA anticipated in 2017. pSivida’s pre-clinical development program is focused on using its core platform technologies Durasert™ and Tethadur™ to deliver drugs and biologics to treat wet and dry age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida please visit www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google+.
Contact: EVC Group Michael Polyviou/Doug Sherk – Investors [email protected]; [email protected] 212.850.6020; 415.652.9100
